Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medivir, Presidio, Tianjin Human-Care Latex Corp. deal

Presidio returned rights to alovudine (MIV-310) to Medivir, while retaining rights to MIV-410.

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE